ALPHAMAB ONCOLO.DL-000002(3NK) News

Date	Title
Dec 30	Alphamab Oncology Announced Anti-HER2 Bispecific ADC JSKN003 Received Approval from CDE to Initiate a Phase III Clinical Study for Ovarian Cancer